Categories: DNAEHRNews

Wave Life Sciences Second Quarter 2023 Financial Results Scheduled for August 3, 2023

CAMBRIDGE, Mass., July 27, 2023 (GLOBE NEWSWIRE) — Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, will host a live webcast and conference call at 8:30 a.m. ET on Thursday, August 3, 2023, to review the company’s second quarter 2023 financial results and provide business updates.

The webcast and conference call may be accessed by visiting “Investor Events” on the investor relations section of the Wave Life Sciences website: ir.wavelifesciences.com/events-and-presentations.

Analysts planning to participate during the Q&A portion of the live call can join the conference call at the following audio conferencing link: available here. Once registered, participants will receive the dial-in information.

Following the live event, an archived version of the webcast will be available on the Wave Life Sciences website.

About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases. Wave aspires to develop best-in-class medicines across multiple therapeutic modalities using PRISM, the company’s proprietary discovery and drug development platform that enables the precise design, optimization, and production of stereopure oligonucleotides. Driven by a resolute sense of urgency, the Wave team is targeting a broad range of genetically defined diseases so that patients and families may realize a brighter future. To find out more, please visit www.wavelifesciences.com and follow Wave on Twitter @WaveLifeSci.

Investor Contact:
Kate Rausch
617-949-4827
krausch@wavelifesci.com

Media Contact:
Alicia Suter
617-949-4817
asuter@wavelifesci.com

Staff

Recent Posts

Optimi Health Announces Appointment of New Director

Vancouver, British Columbia--(Newsfile Corp. - December 18, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX:…

57 minutes ago

Brainomix AI Technology Reveals Efficacy of Novel Neuroprotective Drug Candidate in Severe Acute Ischemic Stroke Patients

Brainomix 360 Stroke imaging was utilized to improve and standardize the grading of baseline stroke…

2 hours ago

BC Platforms and GeneVault partner to unlock access to large-scale real-world and genomic data from under-represented populations

Partnership expands BC Platforms' global patient catchment to include an additional 48 million patient lives…

2 hours ago

EPS Corporation Selects ArisGlobal’s LifeSphere® MultiVigilance

Prominent Japan CRO adopts new safety case processing system to further enhance compliance, automation, and…

2 hours ago

DentScribe Joins Henry Schein One API Exchange as an Authorized Integration Vendor

DentScribe now safely and securely integrates with Dentrix to help dental practices build their best…

2 hours ago

Hemogenyx Pharmaceuticals PLC – Issue of Equity

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE…

5 hours ago